Toll样受体介导补气类方药防治变应性哮喘机制探讨  

Toll-like Receptor Mediated Reinforcing Qi Prescription for Prevention of Allergic Asthma

作　　者：王镓[1] 董竞成[1] 

机构地区：[1]复旦大学附属华山医院,上海200032

出　　处：《中医学报》2014年第9期1262-1266,共5页Acta Chinese Medicine

基　　金：国家自然科学基金资助项目(编号:81173390/H2902);国家重点基础研究发展计划973计划项目(编号:2009CB523001)

摘　　要：补气药对于TLRs的干预具有双向效应:其一通过抑制细胞TLRs的表达活化保护正常组织细胞,其二则通过促进细胞TLRs的表达活化清除各类病理性应激因素。如何能够明确TLRs在变应性哮喘疾病过程中的双向作用和意义,并科学把握患者个体性的病因病机,准确判断其免疫状态病理性改变的具体情况等,成为以TLRs为靶点防治该类疾病中亟待解决的两大瓶颈问题。但在中医学辨证论治个体化诊疗的思想指导下,应用益气类方药合理针对TLRs进行双向调节,可能成为上述两大瓶颈问题的有效解决方案。Reinforcing qi medicine for TLRs intervention has double effects：one is by inhibiting the expression of TLRs activation to protect normal tissue cell. The other one is promoting the expression of TLRs activation to remove all kinds of pathological stress factors, How can clear double function and meaning of TLRs in allergic asthma disease and master the etiology and pathogenesis individuality so as to accurately judging the specific conditions of pathological change of immune state have become the two big bottleneck problems of TLRs as targets for the prevention and control of these conditions. But under the guidance of the individualized diagnosis and treatment of traditional Chinese medicine syndrome differentiation, using Yiqi prescription for reasonable two-way adjustment of TLRs could become the major effective solutions of two bottlenecks.

关 键 词：TOLL样受体 补气类方药 变应性哮喘 

分 类 号：R256.12[医药卫生—中医内科学]